“ With more than 20 years of experience, Alexion is a clear leader in the field of complement biology, and we are very pleased by our collaboration’s success to date in identifying potential new GalXC ...

“Our collaboration with Dicerna to discover and develop GalXC RNAi therapies, which have the potential to inhibit uncontrolled activation of the complement system in new ways, represents an exciting ...